imidazo[1,5-a] quinoxalines / Pfizer - LARVOL DELTA

COVID-19 Vaccine Responsiveness in Patients with Multiple Myeloma and Waldenström Macroglobulinemia (IMW 2021) - "Vaccine-specific S antibody responses following mRNA-1273, BNT162b2, and JNJ-78436735 were 74% (25/34; p<0.05), 51% (24/47; p=NS), and 20% (2/10; p<0.05) in MM and 67% (10/15; p<0.005), 19% (5/27; p<0.05), and 0% (0/3; p=NS) in WM... These preliminary data suggest impaired serologic responses following COVID- 19 vaccines in patients with both MM and WM. Overall, WM patients showed more severe impairment of COVID-19 S antibody responses. Most previously untreated WM patients achieved S antibody responses, however suboptimal antibody responses were seen in WM patients who received rituximab within 12 months or on active BTK inhibitors."

Clinical • Hematological Disorders • Hematological Malignancies • Immunology • Infectious Disease • Lymphoma • Lymphoplasmacytic Lymphoma • Multiple Myeloma • Novel Coronavirus Disease • Oncology • Respiratory Diseases • Waldenstrom Macroglobulinemia